A Phase 4 interventional study of Denosumab Injection and Abaloparatide in Osteoporosis, Postmenopausal, sponsored by Hospital for Special Surgery, New York. Active, not recruiting at 1 site in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Hospital for Special Surgery, New York · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Osteoporosis, Postmenopausal with a site in United States — 4 open to participants now, 11 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · United States.
Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, this one is the 64th largest by planned enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2021, is one of 31 in phase 4, reaches primary completion later than 2 of the 10 other live ones, and was the 91st registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →4 of the 106 studies in Osteoporosis, Postmenopausal with a site in United States are open now. Recruiting first, the newest first:
University of Connecticut · Sites in United States
Ages 45–70 · Women only · Healthy volunteers
Penn State University · Sites in United States
Ages 44–55 · Women only · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 45+ · Women only · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 45+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 45 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 30 · Phase 4 31
First in 1994; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 201 across the 95 interventional studies, 101 across the 8 observational. Of the 92 that completed or were terminated, 49 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 106 have an industry lead sponsor. The 10 most frequent:
Hospital for Special Surgery, New York is the lead sponsor of 226 studies on the registry; 40 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 22 (73%) have results posted.
Hospital for Special Surgery, New York has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
4 of the studies in Osteoporosis, Postmenopausal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
| NCT06558188Massachusetts General HospitalCombined Anabolic Therapy | 2027-11-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of the total hip and lumbar spine at 18 months. Secondary outcomes will include group differences in bone mineral density (BMD) at the femoral neck, trochanter and wrist sites at 6, 12 and 18 months, spine and total hip bone mineral density (BMD) at 6 and 12 months and trabecular bone score (TBS) at 18 months. Secondary outcomes will also include within group changes from baseline for each of these variables. Bone turnover markers will also be measured to demonstrate that PINP levels will increase with administration of abaloparatide even in the setting of ongoing denosumab, while CTX levels will remain low.
Some women on denosumab treatment for osteoporosis remain at high risk for fracture. These include women who sustain incident fractures on denosumab and those who have declining bone mineral density (BMD) or persistently low bone mineral density (BMD), despite treatment. There are few options available for these patients. Denosumab withdrawal is associated with dramatic increased bone remodeling, rapid prominent bone loss, and multiple vertebral fractures (Cummings JBMR 2017). Switching from denosumab to teriparatide is associated with substantial BMD loss in the hip and femoral neck. After 2 years of denosumab treatment, when women are switched to teriparatide, total hip BMD remains below the baseline (at end of denosumab treatment) over the entire 2 years of teriparatide treatment (Leder Lancet 2015).
Abaloparatide might be a better option than teriparatide in patients switching from denosumab, because it is less pro-resorptive than teriparatide, however, hip BMD will still likely decline. Alternatively, adding abaloparatide to ongoing denosumab might be an excellent treatment option for these women. One of the investigators has previously shown that adding teriparatide to ongoing alendronate results in improved BMD and bone strength, compared to switching to teriparatide (Cosman JCEM 2009 and Cosman JBMR 2013). Others have shown that co-administration of teriparatide and denosumab to treatment naïve women increases BMD more than either agent alone (Tsai Lancet 2013, Leder et al JCEM 2014). Based on both of these observations, the investigators believe that adding abaloparatide to continued denosumab treatment will allow bone formation to increase, without increasing bone resorption (modeling-based bone formation) and will produce substantial BMD increments in both spine and hip.
Hypothesis: In women who still appear to be at high risk for fracture while receiving ongoing denosumab therapy, adding abaloparatide will increase BMD of the lumbar spine and total hip significantly more than continuing denosumab alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
Drug: Denosumab Injection
3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
Drug: Denosumab Injection · Drug: Abaloparatide
Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
Also known as: Prolia
Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
Also known as: Tymlos
Bone mineral density changes at total hip and lumbar spine
Group differences in BMD increment at total hip and lumbar spine at 18 months.
Time frame: 18 months
Bone mineral density changes in increments
Group Differences in BMD increments: of lumbar spine and total hip at 6 and 12 months. of femoral neck, and 1/3 radius at 6, 12 and 18 months. Group Differences in BMD increments: of lumbar spine and total hip at 6 and 12 months. of femoral neck, and 1/3 radius at 6, 12 and 18 months. Group Differences in BMD increments: of lumbar spine and total hip at 6 and 12 months. of femoral neck, and 1/3 radius at 6, 12 and 18 months. Group differences in BMD increments of lumbar spine and total hip (at 6 and 12 months) and of femoral neck and 1/3 distal radius (at 6, 12, and 18 months)
Time frame: 6, 12, 18 months
Trabecular Bone Score changes
Group differences in Trabecular Bone Score at 18 months
Time frame: 18 months
Within Group Increments in bone mineral density (vs baseline)
Within Group Increments in bone mineral density vs baseline of lumbar spine (at 6, 12, and 18 months) and of total hip, femoral neck, and distal 1/3 radius (at 6, 12, and 18 months)
Time frame: 6, 12, 18 months
Differences in biochemical bone turnover markers
Within and between group differences in biochemical bone turnover markers (P1NP and CTX) at 3, 6, 12, and 18 months
Time frame: 3, 6, 12, 18 months
Plan to share: No
Ran from Feb 2021 to primary completion in Sep 2026, 67 months.
Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 67 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abaloparatide
Osteoporosis, Postmenopausal →
Hospital for Special Surgery, New York →